Oh come on people?
It met its primary end point. The essential purpose of phase II studies, safety. Even if you are not that impressed by MPS (I am personally most certainly back in PAR for OA, not MPS) it adds positivity to the OA trials via further safety evidence.
It did not FAIL its secondary endpoint(s) as some above suggest it showed improvement over placebo in pain via PROMIS and function via peg-test, the others a bit ambiguous.
This was an 8 vs 5 sample size trial. What were you expecting? Results were never blowing the share price one way or other. Its a win on primary of safety and a small win on some promising secondaries.
IF, massive IF, there is truly MPS partnership interest, as the company has touted, this has done nothing to dissuade that. But more importantly for some investors with the massive mkt potential of OA, more evidence on safety.
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-31
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |